Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

RVMD Price Correlated With Financials For REVOLUTION Medicines

Free historical financial statements for REVOLUTION Medicines Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 10 quarters since 2020. Compare with RVMD stock chart to see long term trends.

RVMD Stock Compared to Quarterly

RVMD Income Statement

Revenue, Net:9116000
Revenue Per Share:0.1039
Selling, General & Admin Expense:10204000
Research & Development Expense:61001000
Total Operating Expenses:71205000
Operating Income:-62089000
Income Taxes:0
Net Income:-61222000
Earnings Per Share, Basic:-0.82
Shares Outstanding, Basic Avg:87697561

RVMD Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:931000
Change in Accounts Receiveable:241000
Net Cash from Operations:-55716000
Net Cash from Operations Per Share:-0.6353
Cash Dividends Paid:0
Net Cash from Financing Activities:1429000
Property, Plant & Equipment Purchases:2526000
Net Cash from Investing Activities:62401000
Net Change in Cash & Equivalents:8114000

RVMD Balance Sheet

Cash and Cash Equivalents:107518000
Short-Term Investments:355652000
Total Current Assets:483046000
Property, Plant & Equipment, Net:15910000
Total Assets:632802000
Accounts Payable:14067000
Total Short-Term Liabilities:63539000
Total Liabilities:133961000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Schroeder Thilo   Director
250,000 sh at $20
$5,000,000
Buy
Kim Lorence H.   Director
50,000 sh at $20
$1,000,000
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
6,057,931 sh
-241,678 sh
-4%
$154,538
-$4,024
Trv Gp III, LLC
5,524,031 sh
 
$140,918
Blackrock Inc.
5,340,288 sh
-134,931 sh
-2%
$136,230
-$1,581
Bellevue Group Ag
3,310,662 sh
-159,500 sh
-5%
$84,455
-$2,889
FMR LLC
2,867,020 sh
-3,234,704 sh
-53%
$73,138
-$80,442
Trv Gp Iv, LLC
1,419,900 sh
 
$36,222
JPMorgan Chase & Co
1,340,615 sh
58,914 sh
5%
$34,200
$1,939
Geode Capital Management, LLC
1,120,941 sh
17,444 sh
2%
$28,595
$820
Harvard Management Co Inc
670,382 sh
 
$17,101
Northern Trust Corp
629,849 sh
68,794 sh
12%
$16,067
$1,945
Dimensional Fund Advisors LP
478,776 sh
298,436 sh
165%
$12,214
$7,674
Charles Schwab Investment Management Inc
444,212 sh
13,134 sh
3%
$11,332
$481
Bessemer Group Inc
438,054 sh
 
$11,175
Candriam Luxembourg S.C.A.
434,204 sh
-16,178 sh
-4%
$11,076
-$260
Bank Of New York Mellon Corp
261,808 sh
-6,749 sh
-3%
$6,679
-$80
Alliancebernstein L.P.
225,668 sh
120,086 sh
114%
$5,757
$3,100
Morgan Stanley
187,769 sh
138,843 sh
284%
$4,790
$3,559
Rafferty Asset Management, LLC
148,622 sh
-8,911 sh
-6%
$3,791
-$174
Mpm Oncology Impact Management Lp
146,041 sh
 
$3,726
Swiss National Bank
113,200 sh
7,700 sh
7%
$2,888
$233
COMPANY PROFILE
1. Organization

Revolution Medicines, Inc. (the Company) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The Company was founded in October 2014 and is headquartered in Redwood City, California. Liquidity The Company has incurred net operating losses in each year since inception. As of March 31, 2022, the Company had an accumulated deficit of $ 510.3 million . Management believes that its existing cash, cash equivalents and marketable securities will enable the Company to fund its planned operations for at least 12 months following the issuance date of these condensed consolidated financial statements. The Company has been able to fund its operations through the issuance and sale of common stock and redeemable convertible preferred stock in addition to upfront payments and research and development cost reimbursement received under the Company’s collaboration agreement with Genzyme Corporation, an affiliate of Sanofi. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development and payments the Company may receive under the Sanofi collaboration agreement or future collaboration agreements, if any. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives. Public offerings In February 2020, the Company closed its initial public offering (IPO), and issued 16,100,000 shares of its common stock (including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares of common stock) at a price to the public of $ 17.00 per share for net proceeds of $ 250.7 million, after deducting underwriting discounts and commissions of $ 19.2 million and expenses of $ 3.8 million. In July 2020, the Company issued and sold 6,900,000 shares of its common stock in an underwritten public offering (including the exercise in full by the underwriters of their option to purchase an additional 900,000 shares of the Company’s common stock) at a price of $ 26.00 per share for net proceeds of $ 167.8 million, after deducting underwriting discounts and commissions of $ 10.8 million and expenses of $ 0.8 million. In February 2021, the Company issued and sold 6,666,666 shares of its common stock in an underwritten public offering (including the exercise in full by the underwriters of their option to purchase an additional 869,565 shares of the Company’s common stock) at a price of $ 45.00 per share for net proceeds of $ 281.1 million, after deducting underwriting discounts and commissions of $ 18.0 million and expenses of $ 0.9 million. In November 2021, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of its common stock, from time to time, with aggregate gross proceeds of up to $ 250 million, through an at-the-market equity offering program (ATM). In 2021, the Company sold an aggregate of 339,302 shares of common stock under the ATM resulting in gross proceeds of $ 10.4 million. After deducting commissions and expenses of $ 0.3 million, net proceeds to the Company were $ 10.1 million. During the three months ended March 31, 2022, the Company did no t issue shares of the Company’s common stock under the ATM.

Data imported from REVOLUTION Medicines Inc. SEC filings. Check original filings before making any investment decision.